SynthesisBMC public health2026
Socioenvironmental determinants of polypharmacy in mental health disorders: a systematic review.
Synthesis in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the past decades, the role of socioenvironmental determinants (SEDs) on shaping mental health outcomes has gained increasing attention. However, their relationship with antipsychotic and psychotropic polypharmacy (PP) remains unknown.
aimThis systematic review aimed to synthesise evidence on the association between SEDs and PP, as well as summarising PP prevalence in patients with mental health disorders (MHDs).
methodA systematic search was conducted in PubMed, Web of Science, CINHAL, PsycINFO and Scopus databases. Literature was also sourced from Google, Google Scholar and the reference lists of included studies. The review included all studies reporting on sociodemographic and SEDs on psychotropic and antipsychotic PP in patients with MHDs. The prevalence rates were computed using medians and interquartile ranges (IQR), while factors associated with PP were summarised in a table.
resultsA total of 65 findings from 57 studies were analysed, 45 examining antipsychotic PP and 20 studied psychotropic PP. The median prevalences of psychotropic and antipsychotic PP were 30.5% (IQR: 18.0-39.5) and 28.1% (IQR: 18.7-42.9), respectively. Additionally, studies targeting inpatients, patients with schizophrenia and those utilising medical records had higher median prevalence rates. Moreover, our review found that family income to poverty ratios, family adverse consequences, Childhood Opportunity Index, social deprivation and area of residence (e.g. rural, metropolitan) were reported to be significant factors of PP in patients with MHDs.
conclusionThough the reported PP prevalence estimates varied, our systematic review showed that psychotropic and antipsychotic PPs are widespread in clinical practices. Additionally, a few SEDs were reported to be significantly associated with PP in patients with MHDs. This highlights the importance of investigating these modifiable factors. Hence, further in-depth exploration of the relationships between SEDs and polypharmacy is required. Evidence generated through such studies informs population-level strategies to reduce PP, improve equity in mental healthcare, and ultimately enhance patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.